Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients

David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, Shazia Ali, Haitao Gao, Rafia Bhore, Jing Xiao, Andrea T. Hooper, Jennifer D. Hamilton, Bret J. Musser, Diana Rofail, Mohamed Hussein, Joseph Im, Dominique Y. Atmodjo, Christina Perry, Cynthia Pan, Adnan Mahmood, Romana Hosain, John D. Davis, Kenneth C. Turner, Alina Baum, Christos A. Kyratsous, Yunji Kim, Amanda Cook, Wendy Kampman, Lilia Roque-Guerrero, Gerard Acloque, Hessam Aazami, Kevin Cannon, J. Abraham Simón-Campos, Joseph A. Bocchini, Bari Kowal, Thomas DiCioccio, Yuhwen Soo, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D. Yancopoulos, for the Trial Investigators
doi: https://doi.org/10.1101/2021.05.19.21257469
David M. Weinreich
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: david.weinreich@regeneron.com
Sumathi Sivapalasingam
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Norton
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shazia Ali
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haitao Gao
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafia Bhore
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Xiao
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea T. Hooper
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer D. Hamilton
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bret J. Musser
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana Rofail
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamed Hussein
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Im
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominique Y. Atmodjo
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Perry
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Pan
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adnan Mahmood
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romana Hosain
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Davis
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth C. Turner
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alina Baum
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christos A. Kyratsous
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yunji Kim
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Cook
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Kampman
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lilia Roque-Guerrero
2Bio-Medical Research, LLC, Miami, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard Acloque
3Universal Medical and Research Center, LLC, Miami, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hessam Aazami
4Hope Clinical Research, Canoga Park, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Cannon
5PMG Research of Wilmington, Wilmington, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Abraham Simón-Campos
6Köhler and Milstein Research/Hospital Agustín O’Horán, Mérida, Yucatán, México
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph A. Bocchini
7Willis-Knighton Physician Network, Shreveport, LA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bari Kowal
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas DiCioccio
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuhwen Soo
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Stahl
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leah Lipsich
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ned Braunstein
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Herman
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George D. Yancopoulos
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; REGEN-COV, retains activity in vitro against emerging SARS-CoV-2 variants of concern.

Methods The phase 3 portion of this adaptive, randomized, master protocol, included 4,057 Covid-19 outpatients with one or more risk factors for severe disease. Patients were randomized to a single treatment of intravenous placebo, or various doses of REGEN-COV, and followed for 28 days. The prespecified hierarchical analysis first compared REGEN-COV 2400mg dose vs concurrent placebo, then compared the 1200mg dose vs concurrent placebo, for endpoints assessing risk of hospitalization or death, and time to symptom resolution. Safety was evaluated in all treated patients.

Results Both REGEN-COV 2400mg and 1200mg significantly reduced Covid-19-related hospitalization or all-cause death compared to placebo (71.3% reduction [1.3% vs 4.6%; p<0.0001] and 70.4% reduction [1.0% vs 3.2%; p=0.0024], respectively). The median time to resolution of Covid-19 symptoms was 4 days shorter in both dose arms vs placebo (10 vs 14 days; p<0.0001). Efficacy of REGEN-COV was consistent across subgroups, including patients who were SARS-CoV-2 serum antibody-positive at baseline. REGEN-COV more rapidly reduced viral load than placebo. Serious adverse events occurred more frequently in the placebo group (4.0%) than in the 1200mg (1.1%) and 2400mg (1.3%) groups and grade ≥2 infusion-related reactions were infrequent (<0.3% in all groups).

Conclusions Treatment with REGEN-COV was well-tolerated and significantly reduced Covid-19-related hospitalization or all-cause death, rapidly resolved symptoms, and reduced viral load.

(Funded by Regeneron Pharmaceuticals and the Biomedical and Advanced Research and Development Authority of the Department of Health and Human Services; ClinicalTrials.gov number, NCT04425629.)

Competing Interest Statement

Disclosure forms provided by the authors will be available with the full text of this article.

Clinical Trial

NCT04425629

Funding Statement

Supported by Regeneron Pharmaceuticals, Inc. Certain aspects of this project have been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under OT number: HHSO100201700020C.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval was obtained from the following ethics review boards: WCG IRB, Puyallup, WA (IRB00000533); Medicasur, Mexico City, Mexico (20CI09012015, CB9012009 & 20CI09012015); Hospital La Mision S.A. de C.V, Monterrey, Mexico (IRB00011076, COBBIOTICA-19-CEI-008-20160729 & 20CI09012015); Providence St Joseph's Health, Renton, WA (STUDY2020000419 & STUDY2020000465); Lifespan - Rhode Island Hospital, Providence, RI (CMTT/PROJ no: 213620); Research Compliance Office, Palo Alto, CA (IRB 5 Registration4593/Eprotocol: 57728); Advarra IRB, Columbia, MD (MOD009333300).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵¶ Risk factors for hospitalization include an age of more than 50 years, obesity, cardiovascular disease (including hypertension), chronic lung disease (including asthma), chronic metabolic disease (including diabetes), chronic kidney disease (including receipt of dialysis), chronic liver disease, and immunocompromised (immunosuppression or receipt of immunosuppressants).

Data Availability

Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to https://vivli.org/.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 06, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients
David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, Shazia Ali, Haitao Gao, Rafia Bhore, Jing Xiao, Andrea T. Hooper, Jennifer D. Hamilton, Bret J. Musser, Diana Rofail, Mohamed Hussein, Joseph Im, Dominique Y. Atmodjo, Christina Perry, Cynthia Pan, Adnan Mahmood, Romana Hosain, John D. Davis, Kenneth C. Turner, Alina Baum, Christos A. Kyratsous, Yunji Kim, Amanda Cook, Wendy Kampman, Lilia Roque-Guerrero, Gerard Acloque, Hessam Aazami, Kevin Cannon, J. Abraham Simón-Campos, Joseph A. Bocchini, Bari Kowal, Thomas DiCioccio, Yuhwen Soo, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D. Yancopoulos, for the Trial Investigators
medRxiv 2021.05.19.21257469; doi: https://doi.org/10.1101/2021.05.19.21257469
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients
David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, Shazia Ali, Haitao Gao, Rafia Bhore, Jing Xiao, Andrea T. Hooper, Jennifer D. Hamilton, Bret J. Musser, Diana Rofail, Mohamed Hussein, Joseph Im, Dominique Y. Atmodjo, Christina Perry, Cynthia Pan, Adnan Mahmood, Romana Hosain, John D. Davis, Kenneth C. Turner, Alina Baum, Christos A. Kyratsous, Yunji Kim, Amanda Cook, Wendy Kampman, Lilia Roque-Guerrero, Gerard Acloque, Hessam Aazami, Kevin Cannon, J. Abraham Simón-Campos, Joseph A. Bocchini, Bari Kowal, Thomas DiCioccio, Yuhwen Soo, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D. Yancopoulos, for the Trial Investigators
medRxiv 2021.05.19.21257469; doi: https://doi.org/10.1101/2021.05.19.21257469

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1090)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9746)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2298)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11618)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2136)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (144)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (692)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (450)
  • Respiratory Medicine (621)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)